Novartis CEO: We're never done with M&A

Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S. administration over potential pharmaceuticals tariffs.

martedì 28 ottobre 2025 New tab

26 words~1 min read

Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG

Get this delivered to your inbox, and more info about our products and services.

Other newsrooms on this story

· 5 sources

Full timeline →

Other newsrooms on this story

· 5 sources

Full timeline →

Related reading

cnbc.com

Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never…

Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.

cnbc.com6 mesi fa

cnbc.com

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than…

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…

cnbc.com6 mesi fa

cnbc.com

Novartis CEO: Confident we are shielded from any further U.S. tariffs

Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs…

cnbc.com3 mesi fa

cnbc.com

Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC

The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.

cnbc.com3 mesi fa

cnbc.com

Commit fully to the role you’re in now, and your career may thank you later:…

Guided by immigrant roots, public‑health purpose and a belief in “staying in the ring,” Novartis CEO Vas Narasimhan reflects on…

cnbc.com2 mesi fa

cnbc.com

Novonesis CEO: Maintaining margins despite macroeconomic headwinds

Ester Baiget, CEO of biosolutions company, Novonesis discusses HY earnings, and explains how the company is navigating…

cnbc.com8 mesi fa